Evidence map›Paper›PMID 40951183›Full record

ArticleCureus2025

Hyperferritinemia as a Clue to Neuroendocrine Carcinoma.

Eugene S Chao, Gene Yoshikawa, Xin Qing, Charity Huang

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eugene S ChaoInternal Medicine, Harbor University of California Los Angeles Medical Center, Torrance, USA.
Gene YoshikawaHematology Oncology, Harbor University of California Los Angeles Medical Center, Torrance, USA.
Xin QingPathology, Harbor University of California Los Angeles Medical Center, Torrance, USA.
Charity HuangHematology Oncology, Harbor University of California Los Angeles Medical Center, Torrance, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferritin is the protein that serves as the main mechanism for iron storage. It can also be an acute-phase reactant, which may rise in response to inflammation, infection, injury, autoimmune disease, or malignancy. Therefore, when evaluating ferritin levels, it is important to consider both iron storage and potential underlying conditions that could cause hyperferritinemia. We report a case of an elderly man in his late 80s who had elevated ferritin levels for years before ultimately being diagnosed with metastatic neuroendocrine carcinoma. The initial diagnosis was suspected to be due to iron overload from iatrogenic causes, but despite discontinuation of iron supplementation, the patient continued to have hyperferritinemia. Broad differential diagnoses were considered, including hereditary hemochromatosis, sideroblastic anemia, thalassemia, viral infection, hereditary hyperferritinemia, myelodysplastic syndromes with ineffective iron regulation, hemophagocytic lymphohistiocytosis, and other autoimmune phenomena. However, workup was negative. Ultimately, bone marrow biopsy was performed, which revealed poorly differentiated metastatic carcinoma with neuroendocrine differentiation.

Indexed as

anemia workuphyperferritinemianeuroendocrine carcinoma of prostateneuroendocrine differentiationpoorly differentiated metastatic carcinoma

Identifiers

PMID40951183
PMCPMC12431798

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.